Delivery Order SPE2DB20D1004-SPE2DB25FNFPU

Award Date 3/14/25
Potential Completion Date 3/17/25
Potential Value $1.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract, valued at $3,430.18, has a period of performance through February 18, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing...
The Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of the pharmaceutical product WEGOVY 0.5 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $9,873.72 and an ultimate completion date of August 27, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025,...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The contract, valued at $3,587.90, has an ultimate completion date of October 30, 2024. This order is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract worth $31,385.30 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of WEGOVY 1 MG/0.5 ML PEN 0.5ML. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a leading global pharmaceutical distribution company, to provide the specialty medication WEGOVY 1 MG/0.5 ML PEN 0.5ML. The $1,773.81 delivery order has an ultimate completion date of March 26, 2024 and is not associated with any set-aside designation. This delivery order is part of a larger $999,999,999.00 indefinite delivery contract (IDC) awarded solely to...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the procurement of WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The contract has a ceiling value of $10,821.72 and a period of performance through January 3, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The contract has a ceiling value of $5,828.89 and a period of performance through April 4, 2024. This delivery order is issued under a larger indefinite delivery contract (IDC) awarded to Amerisourcebergen Drug Corp by DLA, with a potential value of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the drug WEGOVY 1 MG/0.5 ML PEN 0.5ML. The delivery order, worth $14,269.26, has a period of performance through September 26, 2024. It is issued under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which has a ceiling value of up to $999,999,999 and is used to provide a wide range of medical commodities to support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $13,435.84, is for the delivery of the medication WEGOVY 0.25 MG/0.5 ML PEN 0.5ML. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication WEGOVY 2.4 MG/0.75 ML PEN 0.75ML. The fixed-price contract has a ceiling value of $2,261.01 and a period of performance through March 10, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The...
  • SPE2DB20D1004
    Indefinite Delivery Contract
  • SPE2DB20D1004-SPE2DB25FNFPU
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of the medication WEGOVY 1 MG/0.5 ML PEN 0.5ML. The contract has a ceiling value of $1,410.50 and a period of performance through March 17, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which provides a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract did not have a set-aside designation, indicating open competition.

Generated 6/13/25, 10:03 AM